We report an analysis of the value of a second high-dose melphalan autograft, performed at relapse, on a series of newly diagnosed myeloma patients entered into the high-dose program at our center. We conclude that relapse-free survival after the first autograft is a major prognostic factor in determining outcome.
Figures & Tables
Article Information
Vol. 91 No. 1 (2006): January, 2006 : Letters to the Editor
CL Alvares, FE Davies, C Horton, G Patel, R Powles, GJ Morgan. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91(1):141-142; https://doi.org/10.3324/%x.
To create an adaptation, translation, or derivative of the
original work, for commercial e-prints and printed articles further permission is required.
For information contact: marketing@haematologica.org
Other types of copyright management, can be agreed with the Editorial office.
